Quarterly ResultMay 13, 2026, 08:37 AM
Fate Therapeutics Q1 Net Loss $(31.2)M; Operating Expenses Down 20%
AI Summary
Fate Therapeutics reported a Q1 2026 net loss of $(31.2) million, an improvement from $(37.6) million in Q1 2025, driven by a 20% reduction in operating expenses to $34.3 million. The company extended its operating runway into 2028 with $174.8 million in cash and investments. Key clinical advancements include the planned initiation of the Phase 2 RECLAIM-LN trial for FT819 in 2H 2026 and FT819's selection into the FDA's CDRP program, potentially accelerating its registration pathway. Additionally, the company plans to submit an IND for FT839 in 2H 2026 and continues to enroll patients in the FT836 Phase 1 study.
Key Highlights
- Q1 2026 Net Loss was $(31.2) million, an improvement from $(37.6) million in Q1 2025.
- Total operating expenses for Q1 2026 were $34.3 million, a 20% reduction from Q1 2025.
- Cash, cash equivalents, and investments totaled $174.8 million as of March 31, 2026.
- Operating runway extended into 2028.
- RECLAIM-LN, a Phase 2 potentially registrational trial of FT819, is on schedule to initiate in 2H 2026.
- FT819 selected into FDA's CDRP program, enabling early and enhanced CMC communication.
- IND application for FT839 Phase 1 autoimmune study expected in 2H 2026.
- FT836 Phase 1 study enrolling for solid tumors; IIT for multiple myeloma cleared by FDA.